Toxins (mitopodozide), and alkylating agents (procarbazine, triaziquone) by implies with the in vitro shortterm test. As a subsequent step, we performed hierarchical cluster evaluation, which may well be much more suited for an integrated method to understand the complexity of drug resistance. All investigated drugs except doxorubicin were subjected to cluster evaluation (Figure B, left). We divided the dendrogram into six clusters and buy DPC-681 correlated them together with the doxorubicin results. Interestingly, sensitive and resistant tumors have been separated inside the clusters (p . ). Clusters and (n ) were enriched with doxorubicinresistant tumors , whereas clusters and (n ) were enriched with doxorubicinsensitive ones. This indicates that resistance to nine compounds from diverse drug classes (antibiotics, antimetabolites, epipodophyllotoxins, and alkylating agents) drastically correlated with resistance to doxorubicin. This opens the possibility to predict the responsiveness of tumors to a broad array of cytostatic drugs by using solely doxorubicin as a reference drug. To additional explore this phenomenon inside a group of tumors of your identical tumor form, we investigated lung cancers for their response in vitro to doxorubicin, fluorouracil, and OOHcyclophosphamide (Figure B, middle). Cluster evaluation working with the data for fluorouracil and OOHcyclophosphamide permitted the separation of 3 clusters. Once again, we found aFrontiers in Oncology DecemberVolm and EfferthPrediction of Cancer Drug ResistanceTABLe Prognostic value of drug resistance assays. Assay Tumor sort No. of sufferers Prognostic relevance ReferenceMTT assay Extreme drug resistance assay DhistoMicrocystin-LR chemical information culture assay ChemoFxtest Dhistoculture assay MTT assay Dhistoculture assay Threedimensional histoculture Threedimensional histoculture MTT assay Dhistoculture assay MTT assay MTT assay Threedimensional histoculture MTT assay MTT assay ATP luminescence assay MTT assay ATP luminescence assay ATP luminescence assay Collagen gel droplet embedded culture drug sensitvity test (CDDST) ATP luminescence assayOvarian Ca Ovarian Ca Ovarian Ca Ovarian Ca Ovarian Ca Ovarian Ca Peritonitis carcinomatosa Gastric Ca Gastric Ca Gastric Ca Gastric Ca Gastric Ca Gastric Ca Colorectal cancer Colorectal Ca Pancreas Ca Pancreas Ca Esophageal Ca Melanoma Melanoma Lung cancer (NSCLC) Leukemia (ANLL)Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival advantage of sensitive vs. resistant No survival benefit 
of sensitive vs. resistant No survival benefit PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/18257264 of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival advantage of sensitive vs. resistant Sensitive tumors have reduce risk of treatment failure than resistant ones Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival advantage of sensitive vs. resistantTaylor et al. Holloway et al. Nakada et al. Herzog et al. Jung et al. Xu et al. Isogai et al. Kubota et al. Furukawa et al. Abe et al. Kodera et al. Wu et al. Kub.Toxins (mitopodozide), and alkylating agents (procarbazine, triaziquone) by indicates of the in vitro shortterm test. As a next step, we performed hierarchical cluster analysis, which may possibly be much more suited for an integrated method to know the complexity of drug resistance. All investigated drugs except doxorubicin had been subjected to cluster evaluation (Figure B, left). We divided the dendrogram into six clusters and correlated them with the doxorubicin outcomes. Interestingly, sensitive and resistant tumors had been separated within the clusters (p . ). Clusters and (n ) have been enriched with doxorubicinresistant tumors , whereas clusters and (n ) were enriched with doxorubicinsensitive ones. This indicates that resistance to nine compounds from different drug classes (antibiotics, antimetabolites, epipodophyllotoxins, and alkylating agents) substantially correlated with resistance to doxorubicin. This opens the possibility to predict the responsiveness of tumors to a broad selection of cytostatic drugs by using solely doxorubicin as a reference drug. To further discover this phenomenon within a group of tumors with the exact same tumor kind, we investigated lung cancers for their response in vitro to doxorubicin, fluorouracil, and OOHcyclophosphamide (Figure B, middle). Cluster analysis utilizing the data for fluorouracil and OOHcyclophosphamide allowed the separation of three clusters. Again, we identified aFrontiers in Oncology DecemberVolm and EfferthPrediction of Cancer Drug ResistanceTABLe Prognostic value of drug resistance assays. Assay Tumor type No. of individuals Prognostic relevance ReferenceMTT assay Extreme drug resistance assay Dhistoculture assay ChemoFxtest Dhistoculture assay MTT assay Dhistoculture assay Threedimensional histoculture Threedimensional histoculture MTT assay Dhistoculture assay MTT assay MTT assay Threedimensional histoculture MTT assay MTT assay ATP luminescence assay MTT assay ATP luminescence assay ATP luminescence assay Collagen gel droplet embedded culture drug sensitvity test (CDDST) ATP luminescence assayOvarian Ca Ovarian Ca Ovarian Ca Ovarian Ca Ovarian Ca Ovarian Ca Peritonitis carcinomatosa Gastric Ca Gastric Ca Gastric Ca Gastric Ca Gastric Ca Gastric Ca Colorectal cancer Colorectal Ca Pancreas Ca Pancreas Ca Esophageal Ca Melanoma Melanoma Lung cancer (NSCLC) 
Leukemia (ANLL)Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival benefit of sensitive vs. resistant No survival benefit of sensitive vs. resistant No survival benefit PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/18257264 of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival benefit of sensitive vs. resistant Sensitive tumors have lower danger of remedy failure than resistant ones Survival advantage of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival advantage of sensitive vs. resistant Survival benefit of sensitive vs. resistant Survival advantage of sensitive vs. resistantTaylor et al. Holloway et al. Nakada et al. Herzog et al. Jung et al. Xu et al. Isogai et al. Kubota et al. Furukawa et al. Abe et al. Kodera et al. Wu et al. Kub.
